StreetInsider.com News Articles

TD Cowen Reiterates Buy Rating on MediWound Ltd (MDWD)

Thu, 24 Sep 2026 05:56:32 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $25.00 price target on MediWound Ltd (NASDAQ: MDWD).

The analyst comments "We see an increasingly attractive setup into the Phase 3 VALUE interim analysis. Positive EscharEx data could validate its differentiated 4-5 day debridement profile, challenge Santyl’s entrenched ~$400M franchise, unlock a potentially much larger $1B+ VLU opportunity, and generate substantial strategic interest. Reiterate Buy."

For an analyst ratings summary and ratings history on MediWound Ltd click here. For more ratings news on MediWound Ltd click here.

Shares of MediWound Ltd closed at $13.65 yesterday.

MediWound gets $3.3M more from U.S. government for NexoBrid program

Tue, 22 Sep 2026 07:04:16 -0400

MediWound Ltd. (NASDAQ: MDWD) has received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formulation of its NexoBrid® product, according to a company statement.

The supplemental award brings the total program budget to $21.8 million. The funding is non-dilutive and is intended to support development through the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.

NexoBrid is an FDA-approved biologic used for the enzymatic removal of eschar in thermal burns. The room-temperature-stable formulation is being developed as a non-surgical debridement option for battlefield burn care, where cold-chain storage and

MediWound gets $3.3M more from U.S. government for NexoBrid program

Tue, 22 Sep 2026 07:04:16 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

YAVNE, Israel, September 22, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the Company an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid^® as a non-surgical debridement solution for battlefield

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

MediWound's EscharEx Phase III study cleared to continue by safety board

Mon, 14 Sep 2026 07:01:46 -0400

MediWound Ltd. (NASDAQ: MDWD) announced that an independent Data and Safety Monitoring Board (DSMB) completed a pre-specified periodic safety review of its ongoing Phase III VALUE study and recommended the trial continue without modification.

The DSMB did not identify any safety concerns during its review of the study, which is evaluating the safety and efficacy of EscharEx in patients with venous leg ulcers (VLU).

MediWound said it continues to expect the study's pre-specified interim sample-size reassessment and completion of patient enrollment by the end of the first quarter of 2027.

Ofer Gonen, chief executive officer of MediWound, said in a statement: "The DSMB's

MediWound's EscharEx Phase III study cleared to continue by safety board

Mon, 14 Sep 2026 07:01:46 -0400

The DSMB did not identify any safety concerns during its review of the study, which is evaluating the safety and efficacy of EscharEx in patients with venous leg ulcers (VLU).

MediWound said it continues to expect the study's pre-specified interim sample-size reassessment and completion of patient enrollment by the end of the first quarter of 2027.

Ofer Gonen, chief executive officer of MediWound, said in a statement: "The DSMB's

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Mon, 14 Sep 2026 07:00:00 -0400

Independent DSMB Recommends MediWound’s EscharEx^® Phase III VALUE Study Continue Without Modification

DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027

YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the safety and efficacy of EscharEx^® in patients with venous leg

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Mon, 14 Sep 2026 07:00:00 -0400

Independent DSMB Recommends MediWound’s EscharEx^® Phase III VALUE Study Continue Without Modification

DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 02 Sep 2026 07:00:00 -0400

MediWound to Present at the H.C. Wainwright 28^th Annual Global Investment Conference

YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

The fireside chat, moderated by Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright, is scheduled for Monday, September 14, 2026,

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 02 Sep 2026 07:00:00 -0400

MediWound to Present at the H.C. Wainwright 28^th Annual Global Investment Conference

The fireside chat, moderated by Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright, is scheduled for Monday, September 14, 2026,

Form 4 MediWound Ltd. For: Aug 26 Filed by: Hess Shmuel

Fri, 28 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26997775.html

Form 4 MediWound Ltd. For: Aug 26 Filed by: Hess Shmuel

Fri, 28 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26997775.html

Form 144 MediWound Ltd. Filed by: Hess Shmuel

Fri, 28 Aug 2026 06:36:00 -0400

si-local-file:///var/storage/secattach/20260828/26992844.html

Form 144 MediWound Ltd. Filed by: Hess Shmuel

Fri, 28 Aug 2026 06:36:00 -0400

si-local-file:///var/storage/secattach/20260828/26992844.html

Form SCHEDULE 13G/A MediWound Ltd. Filed by: HOLD Alapkezelo Zrt.

Fri, 28 Aug 2026 06:24:00 -0400

si-local-file:///var/storage/secattach/20260828/26992724.html

Form SCHEDULE 13G/A MediWound Ltd. Filed by: HOLD Alapkezelo Zrt.

Fri, 28 Aug 2026 06:24:00 -0400

si-local-file:///var/storage/secattach/20260828/26992724.html

Form SCHEDULE 13G/A MediWound Ltd. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926624.html

Form SCHEDULE 13G/A MediWound Ltd. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926624.html

MediWound Ltd (MDWD) PT Lowered to $30 at Oppenheimer

Fri, 14 Aug 2026 08:33:50 -0400

Oppenheimer analyst Jay Olson lowered the price target on MediWound Ltd (NASDAQ: MDWD) to $30.00 (from $32.00) while maintaining a Outperform rating.

Form 6-K MediWound Ltd. For: Jun 30

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916304.html

Form 6-K MediWound Ltd. For: Jun 30

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916304.html

MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 13 Aug 2026 07:00:00 -0400

EscharEx^® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027

Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid^®

Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed

Conference Call Today at 8:30 a.m. Eastern Time

YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2026, and provided a